1. Medicines
  2. Cardiology
  3. ENTRESTO® (sacubitril/valsartan)
  4. Mode of action

Click here for Prescribing Information

Mode of action

   

Prescribe ENTRESTO® to act directly on the heart and improve its structure and function1

Unbalanced, NPS and RAAS are 2 critical pathways that contribute to HFrEF and loss of pumping function2

Watch the mechanism of action video below to gain a deeper understanding of ENTRESTO’s complementary actions3

 

 

Discover how ENTRESTO can improve the heart’s structure and function, and reverse cardiac remodelling1,4,5

down pointing arrow icon

 

ENTRESTO is indicated in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction.3

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; RAAS, renin-angiotensin-aldosterone system.

References:

  1. Januzzi JL Jr, et al. JAMA 2019;322(11):1085–1095.
  2. Diez J et al. Eur J Heart Fail 2016; 19 (2) 167-176.
  3. ENTRESTO Summary of Product Characteristics. Accessed December 2021 at www.medicines.ie
  4. Desai AS, et al. JAMA 2019;322(11):1077–1084.
  5. Wang Y, et al. J Am Heart Assoc 2019;8(13):e012272.
Rate this content: 
Average: 5 (1 vote)
April 2022 | IE 171971
Print
×

Ask Speakers

×

Medical Information Request

Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.